MALVERN, PA — Annovis Bio (NYSE: ANVS) has regained compliance with New York Stock Exchange listing standards a year after falling below required market capitalization and stockholders’ equity thresholds, removing a potential overhang as the biotechnology company approaches key clinical and regulatory milestones.
The company said the NYSE confirmed that Annovis now meets all continued listing requirements after a series of measures designed to restore its market value and equity position.
Annovis was notified by the exchange in March 2025 that it had fallen out of compliance under NYSE rules after its average global market capitalization remained below $50 million for 30 consecutive trading days while stockholders’ equity was also below $50 million.
The NYSE accepted the company’s remediation plan in June 2025 and granted an 18-month cure period to regain compliance.
According to Annovis, the company implemented corrective actions to improve both market capitalization and stockholders’ equity and submitted required quarterly progress reports to the exchange throughout the process.
The company regained compliance approximately 12 months after receiving the original notice, six months ahead of the deadline established by the NYSE.
Alexander Morin, Annovis’ director of strategic communications, said the company will now focus on upcoming development milestones, including topline results from its Phase III Alzheimer’s disease study and planned regulatory submissions.
Annovis is developing buntanetap, an investigational oral therapy targeting neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease.
The company remains listed on the NYSE under the ticker symbol ANVS.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.